2012 Conference Programme


Thank you to our sponsors

Platinum Sponsor
BXTAccelyon Logo

Gold Sponsors
Boston Scientific logo

Silver Sponsors
Astellas Oncology logo
BD and BARD logo
Elekta Company Logo
Eckert and Ziegler Logo
OSL Company Logo

Bronze Sponsors
Mermaid Medical small logo
mim Software Company Logo
Oncology Imaging Systems logo
SeeDos logo
Varian medical systems logo

2012 Conference Programme


12th UK and Ireland Prostate Brachytherapy Conference Leeds 2012

2012 Presentations and Debate slides can be accessed from the links in red

Friday 23rd March 2012


Registration and buffet reception Royal Armories

Saturday 24th March 2012


8:00-9:00 Registration Royal Armories


9:00-9.10 Welcome and Introduction


9:10-9:50 Dr Peter Grimm: Long Term Comparison of Current Treatment Modalities for Prostate Cancer
Prostate Cancer Center of Seattle

The presentation can be viewed here.

9:50-10:30 Paul Evans Memorial lecture delivered by Professor Peter Hoskin: 'Current status of HDR brachytherapy for prostate cancer in the UK'
Mount Vernon Cancer Centre, Middlesex.

The presentation can be viewed here.

10:30-11:00 Refreshments and exhibition

11:00-11.40 Professor Alvaro Martinez: Prostate and normal tissue constraints to optimize HDR brachytherapy
William Beaumont Hospital, Michigan

The presentation can be viewed here.


Dr Gerard Morton:
How can we best use HDR brachytherapy to escalate dose in intermediate and high risk disease?
Odette Cancer Centre, Toronto

The presentation can be viewed here.

12.30-13.30 Lunch

13.30-14.30 Prize Abstracts: 5 each of ten minutes

  1. Dispelling the Myth: TURP Does not cause Post-BXT Incontinence or Prevent Adequate Implant.
    Eliot Chadwick, St Lukes Cancer Centre, Royal Surrey County Hospital.

  2. Multi-institutional outcomes following LDR brachytherapy in patients with higher risk cancer.
    Ruth Conroy, Christie Hospital, Manchester

  3. The risk of second cancers occurring more than 5 years after I-125 monotherapy for early prostate cancer.
    Hima Musunuru, St James's Institute of Oncology, Leeds.

  4. Impact and recovery of health related quality of life after single fraction HDR brachytherapy and EBRT for prostate cancer.
    Jahangeer Malik, Christie Hospital, Manchester.

  5. Functional MRI guided HDR prostate brachytherapy tumour boost: a feasibility study.
    Joshua Mason, St James's Institute of Oncology, Leeds.

14.30-15.00 Dr Robert Laing and Mr Peter Bownes: Quality Assurance Practice Guidelines for Transperineal Permanent Seed Brachytherapy of Prostate Cancer
St Lukes Cancer Centre, Guildford and St James's Institute of Oncology, Leeds

15.00-15.30 Refreshments and exhibition

15.30-16.00 Mrs Cathy Taylor: Optimising the Design of your Brachytherapy Service
Christie Hospital, Manchester

The presentation can be viewed here.


Debate chaired by Dr David Bottomley: Over the next decade permanent seeds will remain the optimal brachytherapy treatment for early prostate cancer

The debate slide presentations can be viewed here.

For:   Dr Peter Grimm
    Professor Peter Hoskin

Professor Alvaro Martinez
    Dr Gerard Morton


Each presenting for 10 minutes (4-5 slides) with 20 min debate at end

17.15-17.30 Prize abstract presentation and Close

19.30 Conference Dinner at the Royal Armories